Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer By Ogkologos - June 23, 2025 515 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Physicians Debate Recent FDA Approval of an Immune Checkpoint Inhibitor in... March 31, 2021 FDA Proposes Rule Prohibiting Menthol Cigarettes June 27, 2022 EMA Recommends Granting a Marketing Authorisation for Lutetium (177Lu) Vipivotide Tetraxetan October 19, 2022 ‘Inside Edition’ Anchor Thanks Viewer For Pointing Out Lump That Turned... April 24, 2019 Load more HOT NEWS EMA Recommends Extension of Indications for Blinatumomab PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer Woman, 88, Had Been Waving from Her Window for Over a... Alabama’s Ventilator Rationing Plan Discriminates Against Disabled & Ill Patients, Advocacy...
